Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Megan Othus

Showing results (101-110 of 232) with videos related to

Pageof 24
Sort By:
Blood|October 5, 2013
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaSucha Nand, Megan Othus, John E Godwin, et al.
Cancers|July 29, 2025
CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid LeukemiaMargery Gang, Megan Othus, Anne-Chloe Olix, et al.
Bone Marrow Transplantation|December 28, 2022
Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remissionRoland B Walter, Brenda M Sandmaier, Megan Othus, et al.
Bone Marrow Transplantation|January 29, 2025
Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AMLPhuong T Vo, Brenda M Sandmaier, Megan Othus, et al.
Blood Advances|October 7, 2024
Measurable residual disease as predictor of post-day +100 relapses after allografting in adult AMLNaveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, et al.
Bone Marrow Transplantation|November 6, 2019
Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemiaAlexander P Hoffmann, Ashley L Besch, Megan Othus, et al.
Diabetes Care|March 3, 2022
Immune Checkpoint Inhibitors and Risk of Type 1 DiabetesXuan Chen, Alison H Affinati, Yungchun Lee, et al.
Blood|April 6, 2018
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesAbby Statler, Megan Othus, Harry P Erba, et al.
The Annals of Pharmacotherapy|January 13, 2025
Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective AnalysisAshley Chen, Grace Baek, Kathryn Russell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2015
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?Daisuke Araki, Brent L Wood, Megan Othus, et al.
Pageof 24

Showing results (101-110 of 232) with videos related to

Sort By:
Pageof 24
Blood|October 5, 2013
A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemiaSucha Nand, Megan Othus, John E Godwin, et al.
Cancers|July 29, 2025
CD34+ Cell Dose, Measurable Residual Disease, and Outcome After Myeloablative HLA-Matched Peripheral Blood Hematopoietic Cell Transplantation for Adults with Acute Myeloid LeukemiaMargery Gang, Megan Othus, Anne-Chloe Olix, et al.
Bone Marrow Transplantation|December 28, 2022
Comparison of reduced intensity and nonmyeloablative conditioning for adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation in first or second remissionRoland B Walter, Brenda M Sandmaier, Megan Othus, et al.
Bone Marrow Transplantation|January 29, 2025
Relationship between age, conditioning intensity, and outcome after allografting in adults age ≥60 years with AMLPhuong T Vo, Brenda M Sandmaier, Megan Othus, et al.
Blood Advances|October 7, 2024
Measurable residual disease as predictor of post-day +100 relapses after allografting in adult AMLNaveed Ali, Megan Othus, Eduardo Rodríguez-Arbolí, et al.
Bone Marrow Transplantation|November 6, 2019
Early achievement of measurable residual disease (MRD)-negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemiaAlexander P Hoffmann, Ashley L Besch, Megan Othus, et al.
Diabetes Care|March 3, 2022
Immune Checkpoint Inhibitors and Risk of Type 1 DiabetesXuan Chen, Alison H Affinati, Yungchun Lee, et al.
Blood|April 6, 2018
Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studiesAbby Statler, Megan Othus, Harry P Erba, et al.
The Annals of Pharmacotherapy|January 13, 2025
Evaluation of the Toxicity and Outcomes of the Combination of Midostaurin and CLAG-M in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML): A Multicenter Retrospective AnalysisAshley Chen, Grace Baek, Kathryn Russell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 16, 2015
Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?Daisuke Araki, Brent L Wood, Megan Othus, et al.
Pageof 24